Skip to Main Content

Paper Details

Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Clin Cancer Res
112
2012
CEF, CMF, HER2, HER2-E, HER2-enriched (HER2-E), Her2, Her2(+), Her2(+) tumors, Luminal A, anthracycline, basal-like subtypes, basal-like tumors, breast cancer, cyclophosphamide, epirubicin, fluorouracil, methotrexate, node-positive breast cancer, non-HER2-E tumors, reverse transcriptase, tumors, women

Datasets

Release 1.2